FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHAI
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Keegan Fintan  (Last) (First) (Middle)  C/O JAZZ PHARMACEUTICALS PLC  CONNAUGHT HOUSE, 1 BURLINGTON RD, FL.  4  (Street)  DUBLIN 4 L2					Issuer Name and Ticker or Trading Symbol     Jazz Pharmaceuticals plc [ JAZZ ]      Date of Earliest Transaction (Month/Day/Year)     07/08/2014										ationship of Reporting Per k all applicable) Director Officer (give title below) EVP, Technical (			10% Ow Other (s below)	ner
					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)									dividual or Joint/Group Filing (Check App )  Form filed by One Reporting Person Form filed by More than One Repor				n
(City)	(Stat	te) (Z	ip)																
1. Title of Security (Instr. 3) 2. Tran			2. Transa	action	2A Ex r) if a	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			or 5. Am 4 and Secur Benef Owne		nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) o (D)	r Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Ordinary Shares 07/08				2014				M		469	A \$4		83	33,741		D			
Ordinary Shares 07/08				07/08	/2014				S <sup>(1)</sup>		1,991	91 D S		5	31,750			D	
		Та	uble II - D								sed of, onvertib			у О	wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		n of		6. Date Exercisa Expiration Date (Month/Day/Yea		•	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D S (I	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)
					Code	v	(A)		Date Exercisal:		Expiration Date	Title	Amoun or Numbe of Shares						
Nonstatutory Stock Option (right	\$46.83	07/08/2014			M			469	(2)		08/08/2022	Ordinary Shares	469		\$0	8,531		D	

## **Explanation of Responses:**

- 1. The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- 2. This option vests over four years from the grant date of August 9, 2012, with 1/4th vested on August 9, 2013 and the remainder vesting in 36 equal monthly installments thereafter.

## Remarks:

/s/ Larissa Schwartz as attorney in fact for Fintan Keegan 07/10/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.